Title: Study on use of Sublingual Misoprostol to Reduce Blood Loss at Caesarean Delivery in Tertiary Care Centre

Authors: Dr Tabassum Ahmed, Dr Renu Rohtagi, Dr Valya Priyadarshini

 DOI:  https://dx.doi.org/10.18535/jmscr/v5i6.65

Abstract

Objective: This prospective randomized controlled study was carried out with the purpose of assessing the efficacy of sublingual misoprostol in decreasing intraoperative blood loss and the need for additional uterotonic agents at cesarean delivery.

Methods: One hundred 110 women undergoing elective or emergency cesarean delivery were assigned randomly to receive either 600 µg misoprostol or placebo sublingually at the time of cord clamping. Simultaneoulsy oxytocin 20 units (10 units in IV drip and 10 Intramuscular) was given. The primary outcome measures were intraoperative blood loss, need for additional uterotonic agents, and perioperative hemoglobin (Hb) fall.

Results: The maternal demographic factors, indications for cesarean delivery were similar between the two groups. Mean intraoperative blood loss was significantly less in misoprostol group as compared with placebo group (510 ± 100 vs. 670 ± 110 ml). Fewer women needed additional uterotonic agents in misoprostol group (20.2 vs. 40.5 %). Perioperative Hb fall was significantly less in misoprostol group (0.77 ± 0.25 vs. 1.05 ± 0.25 g).

Conclusion: Sublingual misoprostol decreases intraoper-ative blood loss and the need for additional uterotonic agents at cesarean delivery.

Keywords Sublingual misoprostol • Blood loss • Cesarean delivery.

References

1.   1.      Acharya G, Al-Sammarai MT, Patel N, et al. A randomized, controlled trial comparing effect of oral misoprostol and intra-venous syntocinon on intra-operative blood loss during cesarean section. Acta Obstet Gynecol Scand. 2001;80:245-50.

2.      Munn MB, Owen J, Vincent R, et al. Comparison of two oxytocin regimens to prevent uterine atony at cesarean delivery: a ran-domized controlled trial. Obstet Gynecol. 2001;98:386-90.

3.      Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl J Med. 2001;344:38-47.

4.      Zhao Y, Li X, Peng Y. Clinical study on reduction of postpartum bleeding in cesarean section by misoprostol. Zhonghua Fu Chan KeZaZhi. 1998;33:403-5.

5.      Lokugamage AU, Paine M, Bassaw-Balroop K, et al. Active management of the third stage at caesarean section: a randomised controlled trial of misoprostol versus syntocinon. Aust N Z J ObstetGynaecol. 2001;41:411-4.

6.      Hamm J, Russell Z, Botha T, et al. Buccal misoprostol to prevent hemorrhage at cesarean delivery: a randomized study. Am J Obstet Gynecol. 2005;192:1404-6.

7.      Vimala N, Mittal S, Kumar S. Sublingual misoprostol versus oxytocin infusion to reduce blood loss at cesarean section. Int J Gynaecol Obstet. 2006;92:106-10.

8.      Lapaire O, Schneider MC, Stotz M, et al. Oral misoprostol versus intravenous oxytocin in reducing blood loss after emergency cesarean delivery. Int J Gynaecol Obstet. 2006;95:2-7.

9.      Patel A, Goudar SS, Geller SE, et al. Drape estimation versus visual assessment for estimating postpartum hemorrhage. Int J Gynaecol Obstet. 2006;93:220-4.

10.  Fekih M, Jnifene A, Fathallah K, et al. Benefit of misoprostol for prevention of postpartum hemorrhage in cesarean section: a randomized controlled trial [Article in French]. J Gynecol Obstet Biol Reprod. 2009;38:588-93.

11.  Hofmeyr GJ, Giilmezoglu AM, Novikova N, et al. Misoprostol to prevent and treat postpartum hemorrhage: a systematic review and meta-analysis of maternal deaths and dose-related effects. Bull World Health Organ. 2009;87:666-77.

12.  Tang OS, Schweer H, Seyberth HW, et al. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod. 2002;17:332-6.

13.  Schaff EA, DiCenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual adminis-tration. Contraception. 2005;71:22-5.

14.  Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharma-cokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet. 2007;99:S160-7.

15.  Gulmezoglu AM, Forna F, Villar J, et al. Prostaglandins for prevention of postpartum hemorrhage. Cochrane Database Syst Rev. 2007;Issue 3, Art No: CD000494. doi: 10.1002/14651858.

16.  Alfirevic Z, Blum J, Walraven G, et al. Prevention of postpartum hemorrhage with misoprostol. Int J Gynaecol Obstet. 2007. S198-201.

17.  World Health Organization. WHO recommendations for the prevention of postpartum hemorrhage. Geneva: World Health Organization; 2007. p. 40. WHO/MPS/07.06.

18.  Eftekhari N, Doroodian M, Lashkarizadeh R. The effect of sub-lingual misoprostol versus intravenous oxytocin in reducing bleeding after caesarean section. J ObstetGynaecol. 2009;29: 633-6.

Corresponding Author

Dr Tabassum Ahmed

Assistant Professor, Dept. (Obst&Gynae)

NMCH, Patna, Bihar